Matthew Schissler Net Worth 2026: Business, Income and Wealth

A Note Before You Read

There are two people named Matthew Schissler who appear in searches. One is a television actor and producer who appeared in shows like The O.C. and later worked on The Disaster Artist. The other is the subject of this article: Matthew L. Schissler, an American entrepreneur, biotech founder, and private investor who built his career in stem cell banking, advertising, and small-cap investment management.

Some websites have confused the two and published wildly inaccurate information about both. This article is about Matthew L. Schissler, the business executive. Every fact here is verified through SEC filings, Wikipedia, Wall Street Transcript interviews, and Equilar executive profiles.

Who Is Matthew Schissler

He saw cord blood banking before most families had ever heard the term. He built a publicly traded company around it, raised over thirty million dollars, made five major acquisitions, expanded into South America, and earned a semi-finalist position for the Ernst and Young Entrepreneur of the Year award in Los Angeles.

Matthew L. Schissler is an American entrepreneur, investor, and business executive who has spent over two decades building, acquiring, and advising small-cap and mid-cap companies across biotechnology, healthcare, advertising, consumer products, and aviation.

Most people who know his name know it through Cord Blood America, the stem cell preservation company he founded in 2003 and led as Chairman and CEO until 2012. But his career before Cord Blood America, and the portfolio of investments and advisory roles he has built since leaving it, tell a more complete story of someone who has consistently identified opportunities before they became obvious and positioned himself to profit from them over the long term.

He is not famous. He does not appear on Forbes lists or in celebrity profiles. He is exactly the kind of investor and entrepreneur who builds real wealth by staying focused on fundamentals rather than on visibility.

Matthew Schissler Quick Facts

Early Life and Education: Biology, Public Policy, and Maryland

Matthew Schissler was born on June 9, 1971. He attended St. Mary’s College of Maryland, a public liberal arts institution on the western shore of the Chesapeake Bay, from 1989 to 1993. He graduated with a Bachelor of Arts degree in Biology and Public Policy.

This is an unusual combination of subjects that turned out to be exactly the right preparation for the career he would build.

Biology gave him the scientific framework to understand what cord blood stem cells are, why they matter medically, and how the preservation process works at a biological level. Public Policy gave him the regulatory and governance literacy to navigate a healthcare industry that is heavily regulated, politically sensitive, and subject to shifting policy environments.

A business executive who leads a biotech company without understanding the science is dependent on advisors for every technical decision. One who understands the underlying biology can engage directly with researchers, medical directors, and regulators on their own terms. Schissler built Cord Blood America with this dual literacy, and it gave the company credibility that purely finance-driven biotech ventures often lack.

Career Start: Delmarva Broadcasting, TMP Worldwide, and Learning Sales

After graduating from St. Mary’s College in 1993, Matthew Schissler began his career in sales, working at Delmarva Broadcasting, a regional radio and media company. This early work in media sales gave him the direct-to-consumer communication skills and the comfort with the persuasion-based aspects of business that would show up throughout his career.

From 1994 to 2001, he held various management and sales positions at TMP Worldwide, Inc., a personnel staffing and advertising company. TMP Worldwide was a significant organization in the late 1990s and early 2000s, operating in executive search, advertising, and the early development of internet-based recruitment platforms. At the time Schissler was there, the company was navigating the dot-com era, building its digital presence, and managing multiple business lines simultaneously.

Rising to Senior Regional Director at TMP required managing client relationships, building teams, hitting revenue targets, and developing the kind of organizational perspective that comes from working in a complex, fast-moving company. Seven years of that experience gave Schissler the operational and commercial foundation he would need when he started building his own businesses.

RainMakers International: The First Company

In April 2001, Schissler left TMP Worldwide and founded RainMakers International, a direct response advertising agency. He served as President and CEO from the company’s founding until January 2003.

Direct response advertising is the discipline of creating marketing campaigns that generate an immediate, measurable response from the audience. It is a data-driven form of advertising that requires both creative execution and analytical rigor to work. Building an agency in this space meant Schissler was simultaneously managing creative output, client relationships, campaign performance analysis, and business development.

He ran RainMakers for approximately two years before a new opportunity pulled him in a completely different direction.

Cord Blood America: The Company That Defined His Career

In January 2003, Matthew Schissler co-founded Cord Blood America, Inc., commonly known as CBAI. He served as Chairman of the Board and Chief Executive Officer from the company’s inception until 2012, a nine-year leadership tenure that represented the most significant phase of his professional career.

What Cord Blood Banking Actually Is

Understanding CBAI requires understanding what cord blood banking is and why it was genuinely forward-thinking in 2003.

Umbilical cord blood is the blood left in the umbilical cord and placenta after a baby is born. This blood contains stem cells that can be used to treat a range of diseases and conditions, including certain cancers, blood disorders, and immune system deficiencies. At birth, families have a one-time opportunity to collect and preserve these stem cells for potential future medical use.

In 2003, this concept was known within specialized medical communities but was not yet part of mainstream family healthcare decision-making. Most expectant parents had never heard of cord blood banking. The companies offering the service were small, fragmented, and competing in an early market with no dominant player.

Schissler saw this market and built a company specifically to capture it.

Building CBAI Through Acquisitions

Schissler did not just build CBAI organically. He built it through a series of strategic acquisitions that expanded the company’s capacity, geographic reach, and competitive position.

In 2005, CBAI absorbed Cord Partners, Inc., integrating its cord blood preservation services to form a core subsidiary specialized in private family banking of stem cells. This acquisition brought additional inventory, client relationships, and operational infrastructure under the CBAI umbrella.

In 2006, CBAI acquired the assets of Cryobank for Oncologic and Reproductive Donors, gaining approximately 750 umbilical cord blood samples and cryogenic storage infrastructure. This added meaningful scale to CBAI’s storage business.

The company also acquired the assets of CorCell Inc., which was at the time the fourth largest cord blood bank in the United States. Bringing CorCell under CBAI transformed the company from a small player into a genuine industry leader in the private cord blood storage market.

Schissler also expanded internationally, establishing BioCells Argentina as a South American subsidiary of CBAI. This international expansion reflected a belief that cord blood banking’s commercial opportunity was not limited to the United States but would grow globally as awareness of the technology spread.

Across his tenure at CBAI, Schissler raised over thirty million dollars to fund five asset acquisitions, two stock purchases, and three minority investments. Raising thirty million dollars for a small-cap public company in a niche healthcare sector is a genuine achievement that required sophisticated investor relations work, compelling business narrative, and the ability to navigate the requirements of public company reporting and compliance.

CBAI traded on the OTCBB under the ticker symbol CBAI.

The Ernst and Young Recognition

In 2008, at the height of CBAI’s growth, Matthew Schissler was named a semi-finalist for the Ernst and Young Entrepreneur of the Year award in the Los Angeles region. This is a meaningful recognition. The Ernst and Young Entrepreneur of the Year program is one of the most respected business awards programs in the United States, and being selected as a regional semi-finalist reflects genuine peer and panel recognition of entrepreneurial achievement.

Moving to Las Vegas and Stepping Down

During his tenure at CBAI, Schissler made the strategic decision to move the company’s headquarters to Las Vegas, Nevada. This decision was driven primarily by tax advantages and improved business accessibility. Nevada’s tax structure is favorable for businesses compared to California, and Las Vegas provided operational infrastructure that supported the company’s needs at a lower cost.

In 2012, Schissler stepped down from his Chairman and CEO roles at CBAI. He had spent nine years building the company through multiple acquisitions, an international expansion, and significant capital raises. The decision to transition out of the operating CEO role reflected a shift toward a different model of wealth creation, one built on board participation, investment management, and portfolio diversification rather than single-company leadership.

The Investment and Advisory Phase: 2012 to Present

After leaving CBAI, Schissler moved into the next phase of his career, which is defined by a portfolio of investment vehicles, board roles, and advisory relationships across multiple small-cap and mid-cap companies.

Pyrenees Investments LLC

Schissler serves as Managing Member of Pyrenees Investments LLC, a private consulting firm that helps small-cap clients with a broad range of public company functions. This includes helping companies establish operations, build sales and marketing functions, achieve public company compliance, and manage book and record keeping. He also provides introductions to legal, accounting, and finance professionals through his network.

Pyrenees Investments serves over a dozen small-cap clients simultaneously, reflecting a diversified service model that generates consulting and advisory fees from multiple relationships rather than being dependent on any single company’s performance.

Work Your Core Investments LLC

Work Your Core Investments LLC is another private investment vehicle that Schissler founded. This firm focuses on companies exhibiting significant growth potential, deploying capital with a long-term value creation orientation rather than a short-term trading approach.

His securities licenses, the Series 63 and Series 79, qualify him as a registered securities professional and investment banking professional. The Series 79 is specifically the investment banking license, which allows him to engage in activities including mergers and acquisitions advisory, private placements, and other investment banking transactions. These licenses are not cosmetic credentials. They represent regulatory qualification that allows him to engage in professional investment banking activities.

GHS Investments

Schissler holds approximately a 33 percent ownership stake in GHS Investments, a firm involved in small-cap convertible note investments. Convertible notes are a specific financial instrument where loans made to small companies can convert into equity under defined conditions. This is a common early-stage and small-cap financing mechanism, and a 33 percent stake in a firm that specializes in this type of investment represents a meaningful financial position.

Aztec Airways

Schissler serves on the Board of Directors of Aztec Airways Inc., a regional aviation company. Board membership at a private aviation company reflects both his diversification across industries and his value as a strategic advisor beyond the healthcare and biotech sectors where his reputation was initially built.

Big League Wiffle Ball

Perhaps the most distinctive entry on his board portfolio is Big League Wiffle Ball, where he also serves as a Board Member. Big League Wiffle Ball is an organized Wiffle ball league concept that has built a following as an adult recreational sport. This board membership is different in character from his other roles but reflects the kind of early-stage, growth-oriented company that his investment philosophy targets.

Frozen Food Gift Group

In 2009, Schissler co-founded the Frozen Food Gift Group with a partner. The company, which traded publicly on the OTCBB under the ticker FROZ, was a specialty ice cream gifting company shipping ice cream gifts across the United States. Schissler held approximately 36 percent of the company’s ownership and served on the Board of Directors. This venture demonstrated his willingness to deploy capital and operational expertise across completely different product categories from his healthcare background.

China Stem Cells Inc.

Schissler served as President of China Stem Cells Inc. and is a minority shareholder and advisor to the company. This role extends his stem cell industry expertise into the Chinese market, leveraging the technical and regulatory knowledge he built at CBAI in a different geographic context.

IIOT-OXYS Inc.

He has served as a Director of IIOT-OXYS Inc., a company in the industrial Internet of Things and health monitoring technology space. This board role positions him in the technology sector, particularly at the intersection of industrial sensors and healthcare monitoring, which aligns with both his biotech background and his broader interest in growth-oriented technology companies.

Matthew Schissler Net Worth 2026

Matthew Schissler’s net worth in 2026 is estimated between five million and ten million dollars. This is the most defensible range based on what is publicly known about his career, his investment positions, and the income streams available to someone with his professional profile.

Some sources suggest ranges as high as twenty million dollars. Without public financial disclosures or a Forbes profile, those higher estimates cannot be verified. The five to ten million dollar range reflects a realistic picture of an investor and entrepreneur who has spent over two decades in small-cap and private markets, raising capital, taking equity positions, and earning advisory fees, without the single large liquidity event that pushes net worth into the tens or hundreds of millions.

Full Income Breakdown

Why There Is No Single Confirmed Number

This is worth being honest about. Matthew Schissler’s financial profile is almost entirely composed of private investments, private fund management, and board advisory roles. None of these require public financial disclosure. SEC Form 4 filings track insider transactions at public companies he is associated with, but these do not reveal his total net worth, his private fund performance, or his personal assets.

The five to ten million dollar estimate is what careful analysis of his known positions, career compensation structure, and industry benchmarks for his type of work produces. It could be higher. Without public disclosure, certainty is not possible.

What Makes Matthew Schissler’s Career Interesting

Matthew Schissler is interesting not because he became a household name but because he represents a specific and underappreciated archetype of American business success: the serial entrepreneur and small-cap investor who consistently finds opportunities at the edge of mainstream awareness and builds something real around them before the opportunity becomes obvious.

He founded an advertising agency before most people understood direct response marketing. He built a cord blood banking company when most families had never heard of the concept. He raised thirty million dollars for a micro-cap biotech at a time when institutional investors rarely touched that space. He diversified into frozen food gifting, South American biotech, Chinese stem cells, regional aviation, and adult recreational sports leagues.

These are not the glamorous sectors that attract profile writers or Forbes lists. They are the sectors where real operational investors spend time because the valuations are still accessible and the upside potential is real if you understand the businesses well enough to pick the right ones.

His Series 79 investment banking license means he is not just an investor but a qualified professional who can participate in the transaction advisory work that generates the highest per-engagement fees in the financial industry. That credential, combined with over twenty years of public company leadership and advisory experience, makes him a genuinely useful asset to the small-cap companies he works with.

Career Timeline

FAQs

What is Matthew Schissler’s net worth in 2026?

His net worth is estimated between five million and ten million dollars. This comes from his portfolio of private investment funds including Work Your Core Investments LLC and Pyrenees Investments LLC, his 33 percent stake in GHS Investments, board compensation from Aztec Airways and other companies, advisory fees, and legacy equity positions from his nine-year tenure at Cord Blood America.

What is Cord Blood America and what did Matthew Schissler do there?

Cord Blood America Inc., trading as CBAI on the OTCBB, was a company Schissler co-founded in January 2003 that specialized in collecting, processing, and storing umbilical cord blood stem cells for families. He served as Chairman and CEO for nine years and raised over thirty million dollars to fund five acquisitions, expanding the company into the South American market through BioCells Argentina and acquiring CorCell Inc., the fourth largest US cord blood bank at the time.

Where did Matthew Schissler go to school?

He attended St. Mary’s College of Maryland from 1989 to 1993, graduating with a Bachelor of Arts in Biology and Public Policy. This dual-subject degree gave him the scientific literacy to lead a biotech company and the regulatory and governance knowledge to navigate a heavily regulated healthcare industry.

What investment companies does Matthew Schissler run?

He is the founder and Managing Member of Work Your Core Investments LLC and the Managing Member of Pyrenees Investments LLC, which advises over a dozen small-cap public company clients. He also holds approximately 33 percent of GHS Investments, a firm focused on small-cap convertible note investments. He holds Series 63 and Series 79 securities licenses, qualifying him as a registered securities and investment banking professional.

Is there another Matthew Schissler that people confuse him with?

Yes. There is a Matthew Schissler who is a television actor and producer, known for appearing in The O.C. and working on The Disaster Artist. Several websites have incorrectly published information about the actor when profiling the business executive Matthew L. Schissler. This article is about Matthew L. Schissler, the biotech entrepreneur and private investor, whose career is documented through SEC filings, the Wall Street Transcript, Equilar executive profiles, and Wikipedia.

Conclusion

Matthew L. Schissler built his career by being early. Early to direct response advertising. Early to cord blood banking. Early to South American biotech. Early to recognizing that small-cap public companies need experienced operators and advisors who understand both the science and the markets.

He raised over thirty million dollars for a micro-cap biotech before cord blood banking was a mainstream conversation. He acquired the fourth largest cord blood bank in the United States and expanded the company into South America. He earned a semi-finalist position for the most respected entrepreneurship award in Los Angeles. He built a portfolio of private investment funds and advisory relationships that continues to generate income across aviation, sports, technology, and healthcare.

His net worth of five to ten million dollars in 2026 does not reflect a splashy single exit or a viral business moment. It reflects twenty-five years of consistent, disciplined work in the parts of the economy that do not attract profiles but do attract returns for people who know what they are doing.

He is exactly the kind of investor that successful investing actually requires: someone who understands the fundamentals, does the work, and lets the results accumulate quietly over time.